BioPharmSignal logoBioPharmSignal

Biotech News

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX)BioCryst PharmaceuticalsConference / presentation

RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 8:30 a.m. ET.

Related news

BCRXBioCryst Pharmaceuticals2026-09-01 11:00 EST

BioCryst to Present at Upcoming Investor Conference

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

PTCTPTC Therapeutics, Inc.2026-11-02 13:00 EST

PTC Therapeutics to Participate in Upcoming Investor Conferences

ARWRArrowhead Pharmaceuticals2026-09-03 11:30 EST

Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences

EXELExelixis2026-09-01 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

PHARPharming Group2026-09-09 06:00 EST

Pharming Group to participate in September investor conferences

EDITEditas Medicine2026-10-14 13:00 EST

Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

ETONEton Pharmaceuticals2026-11-04 21:30 EST

Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London

BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

TARAProtara Therapeutics2026-09-08 20:05 EST

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

View all latest news

BioCryst Pharmaceuticals

Rare-Disease Drug Development BioCryst Pharmaceuticals discovers, develops and commercializes small-molecule medicines for rare diseases. Its portfolio combines a marketed hereditary angioedema franchise with clinical programs targeting additional protein-mediated disorders. ORLADEYO Commercial Franchise ORLADEYO is an oral preventive...

Recent company news

BCRXBioCryst Pharmaceuticals2026-11-04 21:01 EST

BioCryst to Present at Upcoming Investor Conferences

BCRXBioCryst Pharmaceuticals2026-11-04 12:00 EST

BioCryst Reports Third Quarter 2026 Financial Results

BCRXBioCryst Pharmaceuticals2026-10-29 11:00 EST

BioCryst to Present New Data for ORLADEYO® (berotralstat) and Navenibart at the 2026 American College of Allergy, Asthma & Immunology Annual Scientific Meeting

BCRXBioCryst Pharmaceuticals2026-10-21 20:01 EST

BioCryst to Report Third Quarter 2026 Financial Results on November 4

BCRXBioCryst Pharmaceuticals2026-10-21 11:00 EST

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

Stock data

Close
7.63 USD
Market cap
2.12B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States